|
시장보고서
상품코드
2084665
운동실조증 시장 : 치료법별, 질환별, 판매 채널별, 지역별Ataxia Market, By Treatment Type, By Disease Type, By Distribution Channel, By Geography |
||||||
운동실조증 시장은 2026년에 366억 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 658억 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 8.8%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 366억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 8.80% | 2033년 시장 규모 예측 : | 658억 달러 |
운동실조증이란 뇌의 협응 운동 및 운동 중추(소뇌)에 영향을 미치는 일련의 퇴행성 신경질환을 말합니다. 운동실조증을 앓고 있는 분들은 삼키기, 말하기, 균형 및 협응력 유지에 어려움을 겪습니다. 운동실조증은 그 원인에 따라 후천성 운동실조증, 유전성 운동실조증, 특발성 운동실조증의 세 가지 유형으로 분류됩니다. 후천성 운동실조증은 비타민 결핍증, 두부 외상, 미생물 감염, 뇌종양, 약물이나 알코올 노출 등의 외부 요인에 의해 유발됩니다. 유전성 운동실조증은 운동실조를 유발하는 비정상적인 유전자가 대대로 전해짐으로써 발병합니다. 특발성 운동실조증은 원인이 밝혀지지 않은 질환입니다. 운동 실조와 관련된 증상으로는 협응력 저하, 보행 곤란, 잦은 낙상을 동반하는 균형 감각 장애, 미세 운동 능력 상실, 근육 진전, 발음 불명료, 시각 장애 등이 있습니다. 운동 실조는 어떤 연령대에서든 발병할 가능성이 있으며, 진행성 질환으로 시간이 지남에 따라 악화됩니다.
시장 역학
운동실조증 유병률의 증가, 치료를 위한 신약 개발을 목표로 한 연구개발 활동의 활성화, 그리고 시장에서 활동하는 주요 기업의 인수합병 및 제휴와 같은 비유기적 성장 전략의 확대가 예측 기간 중 전 세계 운동실조증 시장의 성장을 촉진하는 주요 요인이 될 것으로 예상됩니다.
예를 들어 2018년 8월 'Clinical and Translational Neuroscience'지에 게재된 논문에 따르면 2018년 시점에 전 세계 소아의 운동실조증 발생률은 10만 명당 26명으로 추정되며, 그중 상염색체 우성 유전성 소뇌성 운동실조증의 발생률은 10만 명당 2.7명, 열성 유전성 소뇌성 운동실조증의 발생률은 10만 명당 3.3명인 것으로 나타났습니다.
본 조사의 주요 특징
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하고 있는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
- 본 조사에서는 다음 매개변수를 바탕으로 전 세계 운동실조증 시장의 주요 기업 개요을 소개하고 있습니다. : 기업 개요, 재무 실적, 제품 포트폴리오, 시장 입지, 유통 전략, 주요 발전 사항, 전략 및 향후 계획.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 본 세계의 운동실조증 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 운동실조 시장을 분석하는 데 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 개요
제3장 시장 역학·규제·동향 분석
제4장 세계의 운동실조증 시장 : 치료 유형별, 2021-2033년
제5장 세계의 운동실조증 시장 : 질환 유형별, 2021-2033년
제6장 세계의 운동실조증 시장 : 유통 채널별, 2021-2033년
제7장 세계의 운동실조증 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSA 26.07.14Ataxia Market is estimated to be valued at USD 36.6 Bn in 2026 and is expected to reach USD 65.8 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 36.6 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.80% | 2033 Value Projection: | USD 65.8 Bn |
Ataxia refers to a group of degenerative neurological diseases that affect coordination and movement center of the brain (cerebellum). People suffering from ataxia have difficulty in swallowing, speech, and maintaining balance or coordination. Ataxia can be classified into three types on the basis of cause: acquired ataxia, genetic ataxia, and idiopathic ataxia. Acquired ataxia is caused by external factors such as vitamin deficiencies, head trauma, microbial infection, brain tumor, and exposure to drugs or alcohol. Genetic ataxia is caused when a damaged gene which leads to ataxia is passed from one generation to the other. Idiopathic ataxia is a condition wherein the cause is unknown. Few of the symptoms associated with ataxia include decreasing coordination, trouble in walking, impaired balance with frequent falls, loss of fine motor skills, muscle tremors, slurred speech, vision problems, and others. Ataxia can develop at any age and is progressive in nature i.e. it worsens with time.
Market Dynamics
The increasing incidence of ataxia, rising research and development activities for the development of novel therapeutics for the treatment of ataxia, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global ataxia market over the forecast period.
For instance, according to an article published by the Clinical and Translational Neuroscience journal, in August 2018, it is estimated that the global occurrence rate of ataxia is 26/100,000 in children wherein the occurrence rate for dominant hereditary cerebellar ataxia is 2.7/100,000 and the occurrence rate for recessive hereditary cerebellar ataxia 3.3/100,000, as of 2018.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global ataxia market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics, Capsida Biotherapeutics Inc., Larimar Therapeutics, Inc., Healx, Intellia Therapeutics, Inc., Editas Medicine, bluebird bio, Inc., Sanofi, Merck & Co., Inc., H. Lundbeck A/S, Cellectis SA, Bio-Techne, GlaxoSmithKline plc, and Allergan
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global ataxia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ataxia market
Market Segmentation
- By Treatment Type (Revenue, USD Bn, 2021-2033)
- Pharmacotherapy
- Levodopa
- Pramipexole
- Desvenlafaxine
- Venlafaxine
- Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
- Physical Therapy
- Speech Therapy
- Others (Adaptive Devices and Occupational Therapy)
- By Disease Type (Revenue, USD Bn, 2021-2033)
- Friedreich's Ataxia
- Ataxia-telangiectasia
- Spinocerebellar Ataxias
- Episodic Ataxia
- Others (Multiple System Atrophy (MSA))
- By Distribution Channel (Revenue, USD Bn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region (Revenue, USD Bn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Pfizer Inc.
- CRISPR Therapeutics
- Acorda Therapeutics
- Capsida Biotherapeutics Inc.
- Larimar Therapeutics, Inc.
- Healx
- Intellia Therapeutics, Inc.
- Editas Medicine
- bluebird bio, Inc.
- Sanofi
- Merck & Co., Inc.
- Lundbeck A/S
- Cellectis SA
- Bio-Techne
- GlaxoSmithKline plc
- Allergan
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Disease Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Disease Type Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global Ataxia Market, By Treatment Type, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Pharmacotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Segment Trends
- Levodopa
- Pramipexole
- Desvenlafaxine
- Venlafaxine
- Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
- Physical Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Speech Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Others (Adaptive Devices and Occupational Therapy)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
5. Global Ataxia Market, By Disease Type, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Friedreich's Ataxia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Ataxia-telangiectasia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Spinocerebellar Ataxias
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Episodic Ataxia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Others (Multiple System Atrophy (MSA))
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
6. Global Ataxia Market, By Distribution Channel, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
7. Global Ataxia Market, By Region, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- CRISPR Therapeutics
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Acorda Therapeutics
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Capsida Biotherapeutics Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Larimar Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Healx
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Intellia Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Editas Medicine
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- bluebird bio, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- H. Lundbeck A/S
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Cellectis SA
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Bio-Techne
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Allergan
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Pfizer Inc.
- Analyst Views
9. Section
- References
- Research Methodology
- About Us
